10-K: Phathom Pharmaceuticals Reports FY2024 Results, Highlights VOQUEZNA Commercial Progress

Phathom Pharmaceuticals announces its FY2024 results, emphasizing the commercial launch and growing demand for VOQUEZNA.

Summary

• Phathom Pharmaceuticals, a biopharmaceutical company, reported its financial results for the fiscal year ended December 31, 2024.
• The company is focused on developing and commercializing novel treatments for gastrointestinal diseases, with its approved products including VOQUEZNA, VOQUEZNA TRIPLE PAK, and VOQUEZNA DUAL PAK.
• These products contain vonoprazan, a potassium-competitive acid blocker.
• The company initiated the commercial launch of VOQUEZNA for Erosive GERD and H. pylori indications in the fourth quarter of 2023.
• As of February 21, 2025, over 300,000 prescriptions for VOQUEZNA tablets, VOQUEZNA Triple Pak, and VOQUEZNA Dual Pak have been filled since launch, written by more than 20,000 prescribers.
• Over 120 million, or over 80%, of total U.S. commercial lives have access to VOQUEZNA tablets.
• The company submitted a citizen petition in December 2024 requesting the FDA to update Orange Book listings to reflect a ten-year NCE exclusivity period for VOQUEZNA.
• A Phase 2 study investigating VOQUEZNA as a potential treatment for eosinophilic esophagitis (EoE) is planned for the first half of 2025.
• The company's net loss for the year ended December 31, 2024 was $334.3 million, compared to $201.6 million for the previous year.
• As of December 31, 2024, the company had cash and cash equivalents of $297.3 million.
• The company believes its existing cash, cash equivalents, and remaining drawdown under the Loan Agreement, along with anticipated product revenues, will be sufficient to fund operations for at least the next 12 months and reach cash flow positivity.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While there's positive momentum in commercialization and prescription growth, the significant net loss and dependence on future financing create uncertainty.

Positives

• Commercial launch of VOQUEZNA products shows strong physician and patient demand.
• VOQUEZNA tablets have commercial access to over 120 million, or over 80%, of total U.S. commercial lives.
• A Phase 2 study for VOQUEZNA as a treatment for eosinophilic esophagitis (EoE) is planned for the first half of 2025.
• The company believes its existing cash, cash equivalents, and remaining drawdown under the Loan Agreement, along with anticipated product revenues, will be sufficient to fund operations for at least the next 12 months and reach cash flow positivity.

Negatives

• The company's net loss for FY2024 was $334.3 million.
• The company has incurred significant operating losses since inception and anticipates that it will continue to incur substantial operating losses for the foreseeable future and may never achieve or maintain profitability.

Risks

• The company may require additional financing to achieve its goals, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force the company to delay, limit, reduce or terminate its commercialization activities, product development programs, or other operations.
• The Revenue Interest Financing Agreement could limit cash flow available for operations.
• The company currently depends entirely on the success of VOQUEZNA, VOQUEZNA TRIPLE PAK and VOQEUZNA DUAL PAK, which were launched in the fourth quarter of 2023.
• Vonoprazan may not have favorable results in future clinical trials, or receive additional regulatory approvals on a timely basis, if at all.
• The company may not be successful in its efforts to expand its pipeline by identifying additional indications and formulations for which to investigate vonoprazan in the future.
• The company currently has limited experience as a company in commercializing products.
• The company relies on third parties to conduct its preclinical and clinical trials and perform other tasks for the company.
• The company currently engages third-party manufacturers for all of its clinical and commercial supplies.
• The company relies on the Takeda License to provide the company rights to develop and commercialize vonoprazan in the United States, Europe, and Canada.
• If the scope of any patent protection or non-patent regulatory exclusivity the company obtains is not sufficiently broad, or if the company loses or fails to obtain any of its patent protection or non-patent regulatory exclusivity, the company's ability to prevent its competitors from commercializing similar or identical product candidates would be adversely affected.
• The successful commercialization of VOQUEZNA, VOQUEZNA TRIPLE PAK and Voquezna Dual Pak will depend in part on the extent to which governmental authorities and health insurers establish coverage, adequate reimbursement levels and favorable pricing policies.
• If the company fails to comply with reporting and payment obligations for VOQUEZNA, VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK under the Medicaid Drug Rebate Program or other governmental pricing programs, the company could be subject to additional reimbursement requirements, penalties, sanctions and fines.
• The company is subject to various foreign, federal, and state healthcare and privacy laws and regulations, and the company's failure to comply with these laws and regulations could harm its results of operations and financial condition.
• The company is highly dependent on the services of its key executives and personnel, and if the company is not able to retain these members of its management or recruit additional management, clinical and commercial personnel, its business will suffer.
• The trading price of the company's securities is likely to be volatile, and purchasers of its securities could incur substantial losses.

Future Outlook

The company believes its existing cash, cash equivalents, and remaining drawdown under the Loan Agreement, along with anticipated product revenues, will be sufficient to fund operations for at least the next 12 months and reach cash flow positivity.

Industry Context

The report provides insight into the competitive landscape of the biopharmaceutical industry, particularly in the gastrointestinal disease area, noting the presence of major pharmaceutical companies, specialty pharmaceutical companies, and biotechnology firms.

Comparison to Industry Standards

• The report mentions that vonoprazan generated peak net sales of approximately $850 million in Japan, providing a benchmark for potential sales in other markets.
• The report references peak sales for individual PPI brands such as Prilosec ($3.7 billion), Nexium ($3.5 billion), and Prevacid ($3.4 billion) as benchmarks for the potential commercial opportunity for VOQUEZNA.

Stakeholder Impact

• Shareholders: Potential for long-term growth but face risks of dilution and stock price volatility.
• Employees: Job security and potential for career advancement within a growing company.
• Patients: Access to a novel treatment option for gastrointestinal diseases.
• Healthcare Providers: A new tool in their armamentarium for managing acid-related GI disorders.
• Suppliers: Potential for increased business as the company's commercial operations expand.

Next Steps

• Continue commercial efforts of approved VOQUEZNA products.
• Further develop vonoprazan as a first-in-class PCAB in the United States for the treatment of acid-related GI diseases.
• Expand the development of vonoprazan across indications, including EoE, and alternative formulations and packaging.
• Evaluate commercial partnerships to maximize the vonoprazan opportunity outside of the United States.
• In-license or acquisition of additional clinical or commercial stage product candidates for the treatment of GI diseases in a capital efficient manner.

Key Dates